Kornimate/medical-research-clean huggingface dataset:
a study of ca-170 (oral pd-l1, pd-l2 and vista checkpoint antagonist) in patients with advanced tumors and lymphomas

Conditions: Advanced Solid Tumors or Lymphomas

Summary: ca-170 is a rationally designed and orally available, small molecule that directly targets the programmed death-ligands 1 and 2 (pd-l1/pd-l2), and v-domain ig suppressor of t cell activation (vista) immune checkpoints and results in activation of t cell proliferation and cytokine production. this is a multi-center, open-label, phase 1 trial of orally administered ca-170 in adult patients with advanced solid tumors or lymphomas who have progressed or are non-responsive to available therapies and for which no standard therapy exists.


Eligibility criteria:
inclusion criteria: 1. males and females ≥ 18 years of age; 2. life expectancy of at least 3 months; 3. ecog ps ≤ 1; 4. acceptable bone marrow and organ function at screening; 5. ability to swallow and retain oral medications; 6. negative serum pregnancy test in women of childbearing potential; 7. measurable disease; 8. tumor for which standard therapy, including approved anti-pd-1 or anti-pd-l1 therapy, when applicable, does not exist or is no longer effective. for patients enrolling into backfill of dose levels at or below the mtd/rp2d, patients with tumor types known to have a high vista expression (such as metastatic malignant pleural mesothelioma of epithelioid histology). exclusion criteria: 1. prior treatment anti-cancer therapy or use of any investigational agent within the past 28 days or 5 half-lives, whichever is shorter; 2. toxicity from prior chemotherapy that has not resolved to grade ≤ 1; 3. radiotherapy within the last 21 days; 4. primary brain tumors or cns metastases; 5. major or minor surgery \< 28 and \<14 days from the start of treatment, respectively; 6. active autoimmune disease or any medical condition requiring the use of systemic immunosuppressive medications; 7. endocrinopathies, unless on stable hormone replacement therapy; 8. active infection requiring systemic therapy; 9. receipt of live vaccines against infectious diseases within 28 days; 10. hiv positive or an aids-related illness; 11. active/chronic hbv or hcv infection; 12. uncontrolled chf (nyha class 2-4), angina, mi, cva, coronary/peripheral artery bypass graft surgery, tia, or pe in prior 3 months; 13. cardiac dysrhythmias; 14. gastrointestinal disease that interferes with receipt of oral drugs; 15. concomitant malignancy; 16. pregnant or lactating female;

Keywords: mesothelioma pd-l1 vista pd-1
an exploratory study of deep cervical lymphovenous bypass (lvb) in alzheimer's disease

Conditions: Alzheimer Disease

Summary: the main pathological mechanism of alzheimer's disease (ad) is the abnormal deposition of amyloid-beta (aβ) and tau proteins in the brain. recent studies indicate that these two proteins are primarily cleared through the glymphatic system-meningeal lymphatic vessels-deep cervical lymphatic vessels pathway. lymphatic circulation disorders in elderly patients can directly lead to the abnormal deposition of these proteins. deep cervical lymphovenous bypass can improve lymphatic circulation and effectively treat lymphedema. this project aims to verify the effectiveness of 'deep cervical lymphovenous bypass' in treating ad, offering a new surgical treatment method to improve cognitive impairment and the quality of life for ad patients.

alzheimer's disease (ad) is a progressive neurodegenerative disorder that insidiously begins. clinically characterized by memory impairment, aphasia, apraxia, agnosia, and other symptoms, it poses a severe threat to the quality of life of the elderly and brings a heavy burden to society and families. to date, there are no effective methods to prevent, halt, or cure ad. therefore, there is an urgent need to explore new treatment approaches. the definition of the glymphatic system and the discovery of meningeal lymphatic vessels (mlv) have overturned the traditional view of the immune privilege of the central nervous system, offering new clues and hope for the study and treatment of many brain diseases, including ad. the main pathological mechanism of alzheimer's disease (ad) is the abnormal deposition of amyloid-beta (aβ) and tau proteins in the brain. recent research indicates that these two proteins are primarily cleared through the glymphatic system-meningeal lymphatic vessels-deep cervical lymphatic vessels pathway, and lymphatic circulation disorders in elderly patients can directly lead to the abnormal deposition of these proteins. deep cervical lymphovenous bypass can improve lymphatic circulation and effectively treat lymphedema. this project aims to verify the effectiveness of 'deep cervical lymphovenous bypass' in treating ad, providing a new surgical method to improve cognitive impairment and the quality of life for ad patients.

Eligibility criteria:
inclusion criteria: 1. the age ranged from 60 to 80 years, and the time from initial diagnosis to enrollment was more than 12 months 2. the estimated survival time is more than 12 months; 3. the clinically diagnosed patients with mild to severe alzheimer's disease; 4. the imaging examination has the correlation diagnosis evidence; 5. volunteer to participate in the project and sign an informed consent form with the guardian. exclusion criteria: 1. complicated with other severe systemic underlying diseases; 2. unable to tolerate general anesthesia; 3. the pregnant women; 4. recent severe infection or infectious diseases within 4 weeks; 5. unable to complete the evaluator or refused to complete the one-year clinical follow-up. 6. refusal to participate

Keywords: deep cervical lymphovenous bypass alzheimer disease
study of prednisone, vinblastine, doxorubicin, and gemcitabine in elderly patients with advanced stages hodgkin's lymphoma

Conditions: Hodgkin's Disease

Summary: the objectives of this study are to assess the feasibility and efficacy of a combination chemotherapy (pvag) in elderly patients with advanced stages hodgkin's lymphoma.

gemcitabine shows promising activity in patients with relapsed lymphoma either administered as single agent or in combination with other cytotoxic agents. no trial to date evaluated its role in patients with primary hodgkin's lymphoma. we therefore developed a three-weekly regimen based on the standard abvd regimen.

Eligibility criteria:
inclusion criteria: * hodgkin's lymphoma (histologically proven) * clinical stage iib (with risk factors bulky mediastinal mass and/or extranodal involvement), iii, or iv * no prior antitumor therapy * age 60 to 75 years * who performance status 0-2 * normal pulmonary function * written informed consent exclusion criteria: * the following histologies are excluded: lymphocyte predominant hd * leukocytes \< 2,500/microl * platelets \< 100,000/microl

Keywords: lymphoma gemcitabine advanced stages hodgkin's lymphoma elderly
quality of life in patients with chronic urticaria

Conditions: Chronic Urticaria

Summary: urticaria is one of the most frequent presenting complaints in dermatology, allergy, and emergency departments. the term chronic urticaria (cu) is understood as the appearance of recurrent wheals more than twice a week for over 6 consecutive weeks .urticaria is not a single disease but a reaction pattern that represents cutaneous mast cell degranulation, resulting in extravasation of plasma into the dermis. the incidence of chronic urticaria is unknown, but it is thought to occur in 0.1%-3% of the population

chronic urticaria signs and symptoms include: patches of red or white wheals, usually on the face, trunk, arms or legs. wheals vary in size, change shape, and appear and fade repeatedly as the reaction runs its course. itching is common, which may be severe. swelling may occur that causes pain or burning (angioedema), especially inside the throat and around the eyes, cheeks, lips, hands, feet and genitals. it is characterized by a tendency for signs and symptoms to flare with triggers such as heat, exercise and stress as well as a tendency for symptoms to recur frequently and unpredictably, sometimes for months or years the significance of chronic urticaria is sometimes trivialised because it is a non-life-threatening disease, but the condition can be very uncomfortable and interfere with sleep and daily activities. it is one of the most common and frustrating diseases for both patients and physicians chronic urticaria has a major impact on quality of life (qol) , with impact on activities of daily living. chronic urticaria patients reportedly suffer considerable loss of energy, sleep disturbance and emotional upset as well as restrictions in the social life. depression and anxiety are the most common psychiatric diagnoses. these psychiatric disorders could also influence qol

Eligibility criteria:
inclusion criteria: patients with chronic urticaria defined as a 6-week or longer history of daily or almost daily itchy cutaneous weals with individual lesions lasting less than 24 h. age between 18 and 60 years. exclusion criteria: patients who are unable to understand the questions, are unwilling to complete the questionnaire, or who have a psychiatric disorder, or obstructive sleep apnea. patients with malignant or central nervous system disease. patients with cognitive impairment due to a current cerebral or psychotic illness. patients with current psychotherapy . glucocorticoids therapy in the last month.

Keywords: erythema wheal formation vascular reaction of the skin
patients' follow-up after subarachnoid haemorrhage caused by ruptured intracranial aneurysms

Conditions: Intracranial Aneurysms

Summary: after endovascular treatment of the intracranial aneurysm, recanalization may occur, with a risk of recurrent subarachnoid haemorrhage or long-term angiographic recurrences of aneurysms. few data exist on patients' long-term follow-up after subarachnoid haemorrhage caused by ruptured intracranial aneurysms.


Eligibility criteria:
inclusion criteria: * subarachnoid haemorrhage caused by ruptured intracranial aneurysms * endovascular embolization of the aneurysm exclusion criteria: * none
impact of moderate alcohol use on hepatitis c virus (hcv) progression

Conditions: Hepatic Fibrogenesis; Hepatitis C

Summary: the purpose of this study is to determine the effect of moderate alcohol intake on liver disease caused by hcv in terms of speed of progression as compared to those not drinking alcohol.


Eligibility criteria:
inclusion criteria: * outpatient with hcv who is not receiving or planning treatment but is receiving standard of care monitoring every 3 months and is either abstinent from alcohol or drinking only moderately exclusion criteria: * hiv co-infection * treated within the past 6 months * history (hx) of other liver disease * alcohol use greater than 30 g/day or history of binge drinking in the last year * decompensated liver disease
long term effects of hydroxyurea therapy in children with sickle cell disease

Conditions: Sickle Cell Disease

Summary: the primary objectives of this prospective, observational study are (1) to describe the long-term cellular, molecular, and clinical effects of hydroxyurea therapy in sickle cell disease, and (2) to perform hydroxyurea pharmacokinetics studies. this study will follow sickle cell patients being treated with hydroxyurea for a long period of time to evaluate the long-term cellular and molecular effects of the drug on the patients' body. this study will consist of two patient groups. one group will be made up of patients who have received hydroxyurea therapy before entering the study. the second group will be made up of patients who have not received hydroxyurea before study entry.

many years of study have documented the severe effects of sickle cell disease. some of these effects include hemolysis (the break down of red blood cells), blockages in the blood vessels, and damage to the organs systems of the body. hydroxyurea, which is given by mouth, is used to effectively prevent blockages in the blood vessels of patients with sickle cell disease. the hydroxyurea dosage varies and the responses of the body to this drug are not well understood. this study will follow sickle cell patients being treated with hydroxyurea for a long period of time to evaluate the long-term cellular and molecular effects of the drug on the patients' body. this study will consist of two patient groups. one group will be made up of patients who have received hydroxyurea therapy before entering the study (old cohort). the second group will be made up of patients who have not received hydroxyurea before study entry (new cohort). this is not a therapeutic drug trial. subjects for this study will receive hydroxyurea therapy for accepted clinical indications, and will be treated per best clinical management using treatment algorithms established at st. jude children's research hospital and other pediatric sickle cell programs across the united states. hydroxyurea therapy data (such as dosing and duration of therapy) will not be dictated by this study, but will be collected to correlate with long-term outcomes. hydroxyurea dose escalation to a stable mtd will occur according to published guidelines.

Eligibility criteria:
inclusion criteria: * patients from birth up to age 30 years * diagnosis of sickle cell disease * patients who are receiving hydroxyurea therapy or plan to begin hydroxyurea therapy

Keywords: hydroxyurea sickle cell anemia
intrathecal morphine in robot-assisted prostatectomy

Conditions: Prostatic Neoplasms

Summary: this study will investigate the efficacy and safety of intrathecal morphine for the patients undergoing robot-assisted prostatectomy

prostatectomy is the treatment of choice for prostate cancer. the robot-assisted prostatectomy is becoming the most popular surgical method for prostate cancer. the small incision after robot-assisted prostatectomy is thought to reduce the postoperative pain. there is few investigations for the strategy to reduce the postoperative pain of robot-assisted prostatectomy. the intrathecal morphine injection is known to reduce postoperative pain for surgeries like hepatectomy, myomectomy and open prostatectomy. this method, however, is not yet studied for the robot-assisted prostatectomy. this study will investigate the efficacy and safety of intrathecal morphine for the patients undergoing robot-assisted prostatectomy.

Eligibility criteria:
inclusion criteria: * patients scheduled for the open nephrectomy exclusion criteria: * patients with renal insufficiency * patients with coagulopathy * history of any neurologic disorder * history of recent infection in 2 weeks * history of drug abuse * patients who cannot understand the usage of th intravenous patient-controlled analgesia * patients using opioids due to the chronic pain

Keywords: prostatic neoplasms laparoscopy injections, spinal morphine
comparison between ten days sequential treatment and traditional three combined treatment of helicobacter pylori

Conditions: Helicobacter Pylori Infection

Summary: the purpose of this study is to compare the eradication efficacy of 10-day triple therapy with 10-day sequential therapy with tetracycline or metronidazole.

background: antimicrobial resistance has decreased eradication rates for helicobacter pylori infection worldwide. objective: to determine whether sequential treatment eradicates h. pylori infection better than standard triple-drug therapy for adults with dyspepsia or peptic ulcers in taiwanese people. design: randomized, single-blind, prospective controlled trial. setting: a large tertiary referral hospital in eastern taiwan. patients: 450 patients with dyspepsia or peptic ulcers and infected by h. pylori. measurements: 13c-urea breath test, upper endoscopy, histologic evaluation, rapid urease test, bacterial culture, assessment of antibiotic resistance and cyp2c19 genotype of host. intervention: 450 patients with h. pylori infection are randomly assigned to receive one of the following therapeutic schemes: group a (5ra5rct): rabeprazole (20 mg bid) plus amoxicillin (1 g bid) for 5 days, followed by rabeprazole (20 mg bid) plus clarithromycin (500 mg bid) and tetracycline (1g bid) for a further 5 days; group b (5ra5rcm): rabeprazole (20 mg bid) plus amoxicillin (1 g bid) for 5 days, followed by rabeprazole (20 mg bid) plus clarithromycin (500 mg bid) and metronidazole (500mg bid) for a further 5 days; group c as control: rabeprazole (20 mg bid) plus amoxicillin (1 g bid) and clarithromycin (500 mg bid.) for 10 days.

Eligibility criteria:
inclusion criteria: * patient proved with infection of h. pylori in gastric mucosa * adult with signed inform consent exclusion criteria: * woman in breast feeding or pregnancy. * allergy to drugs used in study. * three months without use of any antibiotic agents. * patients under 20 years old.

Keywords: helicobacter pylori antibiotic resistance sequential therapy taiwan
randomized study comparing fluoroscopically-guided versus blinded trochanteric bursa injections

Conditions: Bursitis

Summary: the goals of our research project are to study the relationship, if any, between the success of a tb injection (measured by pain relief and general patient satisfaction) and the method in which it was placed. because fluoroscopy places patients requires a slight risk from radiation exposure and increased cost versus blind injection, it is important to know if there is an advantage to using this technique. the investigators will randomize 64 patients to receive either trochanteric bursa injections with corticosteroid and local anesthetic guided by fluoroscopy, or trochanteric bursa patients to receive trochanteric bursa injections based on landmarks on palpation. the investigators will then determine which method is superior, and whether injecting steroid and local anesthetic into the bursa itself is superior or inferior to injecting it into a tender area outside the bursa.

this will be a randomized, controlled study evaluating the value of fluoroscopy in trochanteric bursa injections. subjects will be recruited solely from the patients we normally see at the blaustein pain treatment center with a clinical diagnosis of gtps. sixty-four patients will be randomized in a 1:1 ratio using sealed envelopes to receive either tb corticosteroid injection done blind or with fluoroscopy. all patients who provide informed consent will be brought into the fluoroscopy suite and placed in the lateral decubitus position. in the patients randomized to receive fluoroscopically guided injections, a 22-gauge needle will be placed into the tb and correct position confirmed by fluoroscopy and contrast injection (1 ml per attempt) before corticosteroid and local anesthetic injection (60 mg of depomedrol and 2.5 ml of 0.5% bupivacaine). in the blinded group, one sham, pulsed fluoroscopic image will be taken of the femur, and the injection will be done based only on physical exam (overlying the area of maximal tenderness) and landmarks. prior to the injection, 1 ml of contrast will be administered and another image taken to determine whether or not the needle is within the bursa, but this will not alter the injection. after contrast administration, the same corticosteroid and bupivacaine injection will be administered. the 2 main questions we propose to answer are: 1) whether using fluoroscopy for tb injections results in improved outcomes (comparison of the 32 patients in each group); and 2) whether injecting into the bursa provides superior results than performing non-bursal injections into the area of maximal tenderness (comparison of 32 patients who receive fluoroscopically-guided bursa injections + those patients whose blinded injection was noted to be intra-bursal vs. those patients whose blinded injection was extra-bursal).

Eligibility criteria:
inclusion criteria: * age \> 18 years * clinical diagnosis of trochanteric bursitis exclusion criteria: * pregnancy * allergy to contrast * untreated coagulopathy

Keywords: bursitis injection fluoroscopy
investigation of differential biology of benign and malignant renal masses using advanced magnetic resonance imaging techniques

Conditions: Kidney Cancer

Summary: the aim of this study is to develop techniques for non-invasive imaging of biology in participants with benign or malignant renal masses based on the novel scanning mri techniques, including recently invented hyperpolarised mri, deuterium metabolic imaging and sodium mri. this imaging study will: 1) acquire imaging data from human tissues following the injection of hyperpolarised 13c pyruvate and use 13c-mri to monitor changes in the ratio of 13c-lactate to 13c-pyruvate; 2) acquire imaging data from human tissues using sodium mri or 3) acquire imaging data from human tissues following the oral consumable of deuterated glucose. data acquired during this physiological study will be used to optimise future imaging protocols.in the uk and possibly in other countries, there are some patients with renal masses that are over treated or undergo unnecessary procedures such as surgery or biopsies, as they are thought to have a malignant tumour or a more aggressive tumour but after the procedure it is found that the mass was benign. the aim of this study is to determine whether one or all of these imaging techniques can differentiate between benign and malignant renal masses with the view to developing the techniques further and hopefully reducing the need for over treatment or unnecessary procedures in patients with benign masses.


Eligibility criteria:
inclusion criteria: * over 18 years old * able to and provide written informed consent to participate * if female, postmenopausal or if women of child bearing potential (wocbp) using a suitable contraception * if male, using a suitable contraceptive method for the duration of the study * radiologically suspected or pathologically confirmed benign or malignant renal masses, as determined by standard clinical practice * capable of undergoing a minimum of one study visit exclusion criteria: * contraindication or inability to tolerate mri * pregnant or actively breast-feeding woman * if using an intrauterine contraceptive device (iucd) as a method of contraception the device should be mri safe at 3 t (researcher to confirm) * clinically significant cardiac, pulmonary or neurological diseases as determined by the investigators * laboratory abnormalities that may impact on the study results * any other significant medical or psychiatric history rendering the subject ineligible as deemed by the investigators